These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1391 related articles for article (PubMed ID: 15106100)

  • 21. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.
    Reisinger KS; Brown ML; Xu J; Sullivan BJ; Marshall GS; Nauert B; Matson DO; Silas PE; Schödel F; Gress JO; Kuter BJ;
    Pediatrics; 2006 Feb; 117(2):265-72. PubMed ID: 16452343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measles, Mumps, and Rubella Serostatus and Response to MMR Vaccination Among HIV-Infected Adults.
    Singh HK; Chiu YL; Wilkin T
    AIDS Patient Care STDS; 2015 Sep; 29(9):461-4. PubMed ID: 26153909
    [No Abstract]   [Full Text] [Related]  

  • 23. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine.
    Shinefield HR; Black S; Kuter BJ
    J Infect Dis; 2008 Mar; 197 Suppl 2():S152-5. PubMed ID: 18419390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Susceptibility to measles, rubella and parotitis in young adults].
    Bayas JM; Vilella A; Vidal J; Nebot X; Carbó JM; Navarro G; Prat A; Asenjo MA; Salleras L
    Med Clin (Barc); 1996 Apr; 106(15):561-4. PubMed ID: 8656753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mumps, measles and rubella vaccination in children with PFAPA syndrome.
    Kraszewska-Głomba B; Matkowska-Kocjan A; Miśkiewicz K; Szymańska-Toczek Z; Wójcik M; Banyś D; Szenborn L
    Vaccine; 2016 Nov; 34(48):5903-5906. PubMed ID: 27997341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of antibodies against measles, mumps and rubella in the childhood population in Singapore, 2008-2010.
    Ang LW; Lai FY; Tey SH; Cutter J; James L; Goh KT
    Epidemiol Infect; 2013 Aug; 141(8):1721-30. PubMed ID: 22999024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
    Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccination with a combined vaccine against measles, mumps and rubella aiming at elimination of the three diseases.
    Böttiger M; Christenson B; Strandell A; Romanus V
    Dev Biol Stand; 1986; 65():37-43. PubMed ID: 3556776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for undervaccination against measles in a large sample of preschool children from rural Bavaria.
    Zucs AP; Crispin A; Eckl E; Weitkunat R; Schlipköter U
    Infection; 2004 Jun; 32(3):127-33. PubMed ID: 15188070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.
    Spoulou V; Giannaki M; Vounatsou M; Bakoula C; Grafakos S
    Bone Marrow Transplant; 2004 Jun; 33(12):1187-90. PubMed ID: 15077129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kinetics of antibody and memory B cell responses after MMR immunization in children and young adults.
    Kakoulidou M; Ingelman-Sundberg H; Johansson E; Cagigi A; Farouk SE; Nilsson A; Johansen K
    Vaccine; 2013 Jan; 31(4):711-7. PubMed ID: 23174196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients.
    King SM; Saunders EF; Petric M; Gold R
    Bone Marrow Transplant; 1996 Apr; 17(4):633-6. PubMed ID: 8722367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in the prevalence of the measles, rubella, varicella-zoster, and mumps virus antibody titers in Japanese pregnant women.
    Hanaoka M; Hisano M; Watanabe N; Sugawara K; Kambe Y; Kanda E; Sago H; Kato T; Yamaguchi K
    Vaccine; 2013 May; 31(19):2343-7. PubMed ID: 23523405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Waning antibody levels and avidity: implications for MMR vaccine-induced protection.
    Kontio M; Jokinen S; Paunio M; Peltola H; Davidkin I
    J Infect Dis; 2012 Nov; 206(10):1542-8. PubMed ID: 22966129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
    Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
    Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age.
    Parment PA; Svahn A; Rudén U; Bråkenhielm G; Storsaeter J; Akesson L; Linde A
    Scand J Infect Dis; 2003; 35(10):736-42. PubMed ID: 14606613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and efficacy of Hoshino strain of mumps vaccine in Iran; two years study.
    Avijgan M; Hafizi M; Moghni M; Kheiri S; Esteghamati A; Sarikhani S
    East Afr J Public Health; 2011 Jun; 8(2):88-91. PubMed ID: 22066292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine.
    Seagle EE; Bednarczyk RA; Hill T; Fiebelkorn AP; Hickman CJ; Icenogle JP; Belongia EA; McLean HQ
    Vaccine; 2018 Feb; 36(6):818-826. PubMed ID: 29317117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 70.